Mylan receives approval for generic Cytomel
Mylan Pharmaceuticals has received approval from the FDA for its abbreviated new drug application (NDA) for liothyronine sodium tablets USP. The drug will be available in the strengths of 5mcg, 25mcg and 50mcg. Liothyronine sodium tablets are the generic version of King Pharmaceuticals’s treatment for thyroid deficiency, Cytomel. The company has started the shipping of the product.
- MDRNA Announces Tentative FDA Approval Of Generic Calcitonin-Salmon Nasal Spray
- Sun Pharma gets FDA nod for generic Tessalon
- Sandoz launches generic Antizol
- Teva sues FDA after denial of generic Risperdal exclusivity
